Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Apr 14, 2024 5:52pm
180 Views
Post# 35988434

RE:RE:New things? Up & coming.

RE:RE:New things? Up & coming.

Thanks for the kind words. Contrary to a few others opinions, I work hard at printing something of substance.
i ,as much as possible qualify an oppinion from fact.
Yes, my estimates have been wrong. 
then again as previous, the PAnCan deal was in the can.
Then unexpectedly the rug was pulled out. Setting of a very unfavourable chain of events.
Both of which 100% unexpected.
imho, they are working hard lining up the cards for phase 3 details & enroment.
it is easy to post Ad Hominem attacks. Hiding behind a handle.
They accomplish nothing, 
To your point, tomorrow would be a great news to wake up to & start the week.
Rather a person posting is 100% accurate or close, is quite frankly not important.
Hard concept ton grasp. The only thing that matters....does the science work well enough to get Pelareorep to market as a cancer therapy?
If the answer was easy, there would be many cures for cancer by now.
What mangement makes / year, where the offices are, who is granting the next ATM or bought deal. 100% irrelivent.
Right now Onc has announced a meeting to discuss next steps to define a phase 3 marketing trial.
That being a document co- authored by existing " collaborators & potential partners"
Meaning a lot of thought put into , making sure the trial has as best chance of success as possible.
Back to the science, Pela has a couple of huge advantages.
1. Is systemically administered. Using standard accepted methods. Pelareorep, only multiplies in tumours. Essentially it will find the cancer.
2. minimal side effects 
3. The recent Gobblet studies alongside Roche tecentriq has shown compelling enough data to warrent very quick acceptance from the PanCan people to grant $5million to open another option.
The PAnCan precession promise program shutdown was a huge setback for onc. 
The recovery from which we will see soon enough.
one thing I have learnt from watching Onc, To expect the unexpected.
The science is very favourable, sooner or later the business model will catch up.
wishing Every one a safe & healthy week ahead.
 



 

<< Previous
Bullboard Posts
Next >>